Considering a reasonable WTP threshold , intermediate dose statin therapy is economically attractive , and should be a priority intervention in prevention of cardiovascular events in Brazil
BACKGROUND Statins have proven efficacy in the reduction of cardiovascular events , but the financial impact of its widespread use can be substantial .
OBJECTIVE To conduct a cost-effectiveness analysis of three statin dosing schemes in the Brazilian Unified National Health System ( SUS ) perspective .
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)
Aims /hypothesisWe estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovascular disease in patients with type 2 diabetes using data from the Collaborative Atorvastatin Diabetes Study (CARDS).Subjects and methods A total of 2,838 patients , who were aged 40 to 75 years and had type 2 diabetes without a documented history of cardiovascular disease and without elevated LDL-cholesterol , were recruited from 32 centres in the UK and Irel and and r and omly allocated to atorvastatin 10 mg daily ( n = 1,428 ) or placebo ( n = 1,410 ) . These subjects were followed-up for a median period of 3.9 years . Direct treatment costs and effectiveness were analysed to provide estimates of cost per endpoint-free year over the trial period for alternative definitions of endpoint , and of cost per life-year gained and cost per quality -adjusted life-year ( QALY ) gained over a patient ’s lifetime . Results Over the trial period , the incremental cost-effectiveness ratio ( ICER ) was estimated to be £ 7,608 per year free of any CARDS primary endpoint ; the ICER was calculated to be £ 4,896 per year free of any cardiovascular endpoint and £ 4,120 per year free of any study endpoint . Over lifetime , the incremental cost per life-year gained was £ 5,107 and the cost per QALY was £ 6,471 ( costs and benefits both discounted at 3.5 % ) . Conclusions /interpretation Primary prevention of cardiovascular disease with atorvastatin is a cost-effective intervention in patients with type 2 diabetes , with the ICER for this intervention falling within the current acceptance threshold ( £ 20,000 per QALY ) specified by the National Institute for Health and Clinical Excellence ( NICE )
Considering a reasonable WTP threshold , intermediate dose statin therapy is economically attractive , and should be a priority intervention in prevention of cardiovascular events in Brazil
BACKGROUND Statins have proven efficacy in the reduction of cardiovascular events , but the financial impact of its widespread use can be substantial .
OBJECTIVE To conduct a cost-effectiveness analysis of three statin dosing schemes in the Brazilian Unified National Health System ( SUS ) perspective .